Abstract
HER2 (v-erb-b2 erythroblastic leukemia viral oncogene) is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. Since the discovery of a role for HER2 and other EGF receptors in the development and progression of cancer, they have become targets for a number of targeted anti-cancer drugs. These drugs have proven to be effective in treating and managing a range of cancers, however, recent observations in the clinic have suggested that their administration causes many toxicities, including gastrointestinal toxicity. Drugs with HER2 inhibitory activity fall into two categories; the monoclonal antibodies and small molecule tyrosine kinase inhibitors. Both of these drug classes have been shown to induce symptoms consistent with mucositis development; including nausea and vomiting, diarrhoea and abdominal pain. However, to date, limited studies have been carried out to justify the source of these toxicities. This review summarizes our current knowledge of the toxicities associated with commonly used HER2 targeted therapy drugs, the role of HER2 in cancer and the healthy gastrointestinal tract and the possible mechanisms by which drugs with HER2 inhibitory activity can induce gastrointestinal damage and possibly mucositis in patients.
Keywords: HER2, targeted anti-cancer therapy, toxicity, gastrointestinal tract, mucositis
Current Drug Targets
Title: HER2 Targeted Therapies for Cancer and the Gastrointestinal Tract
Volume: 10 Issue: 6
Author(s): Noor Al-Dasooqi, Rachel Gibson, Joanne Bowen and Dorothy Keefe
Affiliation:
Keywords: HER2, targeted anti-cancer therapy, toxicity, gastrointestinal tract, mucositis
Abstract: HER2 (v-erb-b2 erythroblastic leukemia viral oncogene) is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. Since the discovery of a role for HER2 and other EGF receptors in the development and progression of cancer, they have become targets for a number of targeted anti-cancer drugs. These drugs have proven to be effective in treating and managing a range of cancers, however, recent observations in the clinic have suggested that their administration causes many toxicities, including gastrointestinal toxicity. Drugs with HER2 inhibitory activity fall into two categories; the monoclonal antibodies and small molecule tyrosine kinase inhibitors. Both of these drug classes have been shown to induce symptoms consistent with mucositis development; including nausea and vomiting, diarrhoea and abdominal pain. However, to date, limited studies have been carried out to justify the source of these toxicities. This review summarizes our current knowledge of the toxicities associated with commonly used HER2 targeted therapy drugs, the role of HER2 in cancer and the healthy gastrointestinal tract and the possible mechanisms by which drugs with HER2 inhibitory activity can induce gastrointestinal damage and possibly mucositis in patients.
Export Options
About this article
Cite this article as:
Al-Dasooqi Noor, Gibson Rachel, Bowen Joanne and Keefe Dorothy, HER2 Targeted Therapies for Cancer and the Gastrointestinal Tract, Current Drug Targets 2009; 10 (6) . https://dx.doi.org/10.2174/138945009788488440
DOI https://dx.doi.org/10.2174/138945009788488440 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms for Radioprotection by Melatonin; Can it be Used as a Radiation Countermeasure?
Current Molecular Pharmacology Oxidative and Non-Oxidative Metabolomics of Ethanol
Current Drug Metabolism Decreased Serum Adiponectin Level Affected Clinical Pathological Characteristics of Patients with Gastric Cancer
Current Proteomics Metastasis-Initiating Cells in Renal Cancer
Current Signal Transduction Therapy Rab GTPases, Membrane Trafficking and Diseases
Current Drug Targets Nano-pharmaceutical Formulations for Targeted Drug Delivery against HER2 in Breast Cancer
Current Cancer Drug Targets Electroporation Gene Therapy Preclinical and Clinical Trials for Melanoma
Current Gene Therapy The Role of the PERK/eIF2α/ATF4/CHOP Signaling Pathway in Tumor Progression During Endoplasmic Reticulum Stress
Current Molecular Medicine Evaluating the Susceptibility of Mitochondrial DNA Germline Mutations in Chinese Cancer Patients
Current Molecular Medicine Cervical Squamous Intraepithelial Lesions Among HIV-Positive Women on Antiretroviral Therapy in Kenya
Current HIV Research Potential Role of MEK Inhibition in Treating Patients with Colorectal Cancer
Current Cancer Therapy Reviews Cancer Gene Therapy with Tissue Inhibitors of Metalloproteinases (TIMPs)
Current Gene Therapy Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management
Current Vascular Pharmacology Nanomaterials in the Pharmaceuticals: Occurrence, Behaviour and Applications
Current Pharmaceutical Design Molecular Link Mechanisms between Inflammation and Cancer
Current Pharmaceutical Design N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Anatomical, Biochemical and Physiological Considerations of the Colon in Design and Development of Novel Drug Delivery Systems
Current Drug Delivery Targeted Drug Delivery to the Virus-Infected Airway; Complications and Remedies
Current Drug Delivery TLR4-directed Molecular Strategies Targeting Skin Photodamage and Carcinogenesis
Current Medicinal Chemistry Bleomycin and its Role in Inducing Apoptosis and Senescence in Lung Cells - Modulating Effects of Caveolin-1
Current Cancer Drug Targets